Business Wire

NY-NTT

29.3.2021 10:02:06 CEST | Business Wire | Press release

Share
NTT Named a Leader in the Gartner Magic Quadrant for Network Services, Global Ranked Highest in Gartner Critical Capabilities for Network Services, Global

NTT , a world-leading global technology services provider, today announced it is positioned as a Leader in the March 2021 Gartner ‘Magic Quadrant for Network Services, Global’ report , recognized for both its “Completeness of Vision” and “Ability to Execute.” NTT is also ranked highest in the March 2021 Gartner Critical Capabilities for Network Services, Global report for the Global Network, Intra-Asia/Pacific Network and Intra-EMEA Network Use Cases.

The Gartner Magic Quadrant report states, “Driven by cloud IT service adoption and accelerated by COVID-19, the market for global enterprise network services is undergoing a generational shift in technologies and provider landscape. I&O (Infrastructure & Operations) leaders must adapt their network sourcing approaches to reflect this transformation.”

NTT continues to invest heavily in its global network services portfolio as a transformational driver of innovation for its clients. Known for its exceptional client service and support, NTT has deep expertise in building and managing large, distributed networks. For enterprise CIOs and CDOs pursuing a cloud-first strategy, NTT networking services offer seamless performance for end-users to cloud and SaaS applications, offering a secure, reliable, and enhanced experience whether connecting from home, a branch office, or a large campus.

Masaaki Moribayashi, Senior Executive Vice President for Services for NTT Ltd. said, “Networking is core to delivering agile and impactful solutions for our clients’ rapidly changing business needs. With years of continued investment in our global network services portfolio, it’s a great honor to us to see NTT’s vision, strategy and product portfolio has been well recognized.”

Takeshi Wakita, Senior Vice President for NTT’s Global Network business division, added, “Transformation has always been the foundation of innovation for NTT. We’re incredibly grateful for the hard work of our employees and deep partnership with our clients that allows us to continually raise the bar for our services and offerings.”

For complimentary copies of both reports, click here .

Sources:
1 Gartner, Magic Quadrant for Network Services, Global, Neil Rickard, Bjarne Munch, Danellie Young, 2 March 2021.
2 Gartner, Critical Capabilities for Network Services, Global, Danellie Young, Bjarne Munch, Lisa Pierce, 3 March 2021

Disclaimer

Gartner does not endorse any vendor, product or service depicted in its research publications, and does not advise technology users to select only those vendors with the highest ratings or other designation. Gartner research publications consist of the opinions of Gartner's research organization and should not be construed as statements of fact. Gartner disclaims all warranties, expressed or implied, with respect to this research, including any warranties of merchantability or fitness for a particular purpose.

About NTT

NTT believes in contributing to society through our business operations by applying technology for good. Our services help clients accelerate their growth and develop new business models.

These services include digital business consulting, technology and managed services for cybersecurity, applications, workplace, cloud, data center and networks – all supported by our deep industry expertise, innovation and solutions.

As a top 5 global technology and business solutions provider, our diverse teams deliver services in over 190 countries and regions. We serve 80%+ of Fortune Global 100 companies and thousands of other clients and communities around the world. For more information on NTT, visit www.global.ntt/

Link:

ClickThru

Social Media:

https://www.facebook.com/globalntt

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release

Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s

Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 11:18:00 CEST | Press release

Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0

FPT Launches Flezi Foundry™, Advancing AI-Augmented Delivery for Global Enterprises22.5.2026 10:11:00 CEST | Press release

Global IT corporation FPT announced the launch of Flezi Foundry™ (FPT Digital Foundry™), an AI-augmented delivery platform for software development and IT operations. Built around a governed Service-as-a-Software model, the platform combines autonomous AI agents, human expert oversight, secure infrastructure, and outcome-based delivery mechanisms to help enterprises modernize technology delivery as AI agents become part of software engineering and IT operations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521235556/en/ Flezi Foundry applies Agentic Engineering, a structured delivery approach for software development and IT operations. The model brings AI agents into delivery workflows with human supervision, governance, transparency, and performance measurement built into the process. Flezi Foundry operates through two service modes: Agentic Development Lifecycle (ADLC) supports software development by using specialize

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye